Cargando…

External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis

BACKGROUND: Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). AIM: To independently evaluate the predictive performan...

Descripción completa

Detalles Bibliográficos
Autores principales: Gazda, Jakub, Janicko, Martin, Drazilova, Sylvia, Grgurevic, Ivica, Kanizaj, Tajana Filipec, Koller, Tomas, Bodorovska, Beatrica, Mijic, Maja, Mikolasevic, Ivana, Stromar, Ivana Knezevic, Kucinsky, Branislav, Gazda, Matej, Jarcuska, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245238/
https://www.ncbi.nlm.nih.gov/pubmed/34258254
http://dx.doi.org/10.1155/2021/9928065
_version_ 1783716075036213248
author Gazda, Jakub
Janicko, Martin
Drazilova, Sylvia
Grgurevic, Ivica
Kanizaj, Tajana Filipec
Koller, Tomas
Bodorovska, Beatrica
Mijic, Maja
Mikolasevic, Ivana
Stromar, Ivana Knezevic
Kucinsky, Branislav
Gazda, Matej
Jarcuska, Peter
author_facet Gazda, Jakub
Janicko, Martin
Drazilova, Sylvia
Grgurevic, Ivica
Kanizaj, Tajana Filipec
Koller, Tomas
Bodorovska, Beatrica
Mijic, Maja
Mikolasevic, Ivana
Stromar, Ivana Knezevic
Kucinsky, Branislav
Gazda, Matej
Jarcuska, Peter
author_sort Gazda, Jakub
collection PubMed
description BACKGROUND: Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). AIM: To independently evaluate the predictive performance of the URS model. METHODS: We used a cohort of Slovak and Croatian treatment-naïve PBC patients to quantify the discrimination ability using the area under receiver operating characteristic curve (AUROC) and its 95% confidence interval (CI). Furthermore, we evaluated the calibration using calibration belts. The primary outcome was treatment response after 12 months of UDCA therapy defined as values of alkaline phosphatase ≤1.67 × upper limit of normal. RESULTS: One hundred and ninety-four patients were included. Median pretreatment age was 56 years (interquartile range 49–62). Treatment response was achieved in 79.38% of patients. AUROC of the URS was 0.81 (95% CI 0.73–0.88) and the calibration belt revealed that response rates were correctly estimated by predicted probabilities. CONCLUSION: Our results confirm that the URS can be used in treatment-naïve PBC patients for estimating the treatment response probability after 12 months of UDCA therapy.
format Online
Article
Text
id pubmed-8245238
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-82452382021-07-12 External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis Gazda, Jakub Janicko, Martin Drazilova, Sylvia Grgurevic, Ivica Kanizaj, Tajana Filipec Koller, Tomas Bodorovska, Beatrica Mijic, Maja Mikolasevic, Ivana Stromar, Ivana Knezevic Kucinsky, Branislav Gazda, Matej Jarcuska, Peter Can J Gastroenterol Hepatol Research Article BACKGROUND: Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). AIM: To independently evaluate the predictive performance of the URS model. METHODS: We used a cohort of Slovak and Croatian treatment-naïve PBC patients to quantify the discrimination ability using the area under receiver operating characteristic curve (AUROC) and its 95% confidence interval (CI). Furthermore, we evaluated the calibration using calibration belts. The primary outcome was treatment response after 12 months of UDCA therapy defined as values of alkaline phosphatase ≤1.67 × upper limit of normal. RESULTS: One hundred and ninety-four patients were included. Median pretreatment age was 56 years (interquartile range 49–62). Treatment response was achieved in 79.38% of patients. AUROC of the URS was 0.81 (95% CI 0.73–0.88) and the calibration belt revealed that response rates were correctly estimated by predicted probabilities. CONCLUSION: Our results confirm that the URS can be used in treatment-naïve PBC patients for estimating the treatment response probability after 12 months of UDCA therapy. Hindawi 2021-06-22 /pmc/articles/PMC8245238/ /pubmed/34258254 http://dx.doi.org/10.1155/2021/9928065 Text en Copyright © 2021 Jakub Gazda et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gazda, Jakub
Janicko, Martin
Drazilova, Sylvia
Grgurevic, Ivica
Kanizaj, Tajana Filipec
Koller, Tomas
Bodorovska, Beatrica
Mijic, Maja
Mikolasevic, Ivana
Stromar, Ivana Knezevic
Kucinsky, Branislav
Gazda, Matej
Jarcuska, Peter
External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
title External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
title_full External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
title_fullStr External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
title_full_unstemmed External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
title_short External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
title_sort external validation of udca response score in slovak and croatian patients with primary biliary cholangitis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245238/
https://www.ncbi.nlm.nih.gov/pubmed/34258254
http://dx.doi.org/10.1155/2021/9928065
work_keys_str_mv AT gazdajakub externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis
AT janickomartin externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis
AT drazilovasylvia externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis
AT grgurevicivica externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis
AT kanizajtajanafilipec externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis
AT kollertomas externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis
AT bodorovskabeatrica externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis
AT mijicmaja externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis
AT mikolasevicivana externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis
AT stromarivanaknezevic externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis
AT kucinskybranislav externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis
AT gazdamatej externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis
AT jarcuskapeter externalvalidationofudcaresponsescoreinslovakandcroatianpatientswithprimarybiliarycholangitis